Insider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells 1,403 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Verneuil Vanina De sold 1,403 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $7.20, for a total value of $10,101.60. Following the transaction, the executive vice president now directly owns 63,717 shares of the company’s stock, valued at $458,762.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Verneuil Vanina De also recently made the following trade(s):

• On Tuesday, November 5th, Verneuil Vanina De sold 2,347 shares of Vir Biotechnology stock. The stock was sold at an average price of $9.47, for a total value of $22,226.09.

Vir Biotechnology Price Performance

VIR stock traded up $0.27 during midday trading on Tuesday, reaching $9.64. 1,110,639 shares of the company were exchanged, compared to its average volume of 1,024,860. Vir Biotechnology, Inc. has a one year low of $7.12 and a one year high of $13.09. The firm has a market capitalization of $1.32 billion, a price-to-earnings ratio of -2.46 and a beta of 0.46. The business has a 50-day moving average price of $7.77 and a two-hundred day moving average price of $8.88.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The company had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business’s quarterly revenue was down 9.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.22) EPS. As a group, analysts anticipate that Vir Biotechnology, Inc. will post -3.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the company. Nordea Investment Management AB grew its stake in shares of Vir Biotechnology by 58.7% in the first quarter. Nordea Investment Management AB now owns 235,664 shares of the company’s stock valued at $2,408,000 after acquiring an additional 87,190 shares in the last quarter. Texas Permanent School Fund Corp increased its holdings in shares of Vir Biotechnology by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company’s stock worth $760,000 after purchasing an additional 1,012 shares during the period. Duality Advisers LP raised its position in shares of Vir Biotechnology by 6.7% in the first quarter. Duality Advisers LP now owns 101,479 shares of the company’s stock valued at $1,028,000 after buying an additional 6,331 shares in the last quarter. Empowered Funds LLC boosted its stake in shares of Vir Biotechnology by 8.2% in the first quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock valued at $4,640,000 after buying an additional 34,640 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Vir Biotechnology during the first quarter worth approximately $119,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Wall Street Analyst Weigh In

VIR has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Monday. Barclays lowered their price objective on shares of Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Friday. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).